|
|
|
|
|
Xenexus Pharmaceuticals, drugs, treatment, neurological disorders, alzheimer's, parkinson's, multiple sclerosis, MS
Management
Dr Michael L. Selley, Ph.D. — Chief Executive Officer
Dr Selley has considerable experience in pharmaceutical research and development. He was previously the Founder and Chief Scientific Officer of Nuon Therapeutics, Inc. Dr Selley has served as Chief of Staff to the Australian Minister for Science and Technology and held academic appointments at the John Curtin School of Medical Research in the Institute of Advanced Studies at the Australian National University. Dr Selley has also worked in the international pharmaceutical industry.
Board of Directors
Prof. Sir Marc Feldmann, F.Med.Sci., F.A.A., F.R.S.
Prof. Feldmann is a Professor and the Director of the Kennedy Institute of Rheumatology at Imperial College, London. Prof. Feldmann, together with his collaborator, Prof. Ravinder Maini, was awarded the Crafoord Prize in 2000 and the Albert Lasker Award for Clinical Medical Research in 2003 for their discovery that anti-TNF therapy was an effective treatment for rheumatoid arthritis. Prof. Feldmann was European Inventor of the Year in the lifetime achievement category and was awarded the John Curtin Medal of the Australian National University in 2007. He is a Co-Founder of Nuon Therapeutics, Inc.
Dr Michael L. Selley, Ph.D.
Dr Selley has considerable experience in pharmaceutical research and development. He was previously the Founder and Chief Scientific Officer of Nuon Therapeutics, Inc. Dr Selley has served as Chief of Staff to the Australian Minister for Science and Technology and held academic appointments at the John Curtin School of Medical Research in the Institute of Advanced Studies at the Australian National University. Dr Selley has also worked in the international pharmaceutical industry.
Scientific Advisory Board
Prof. Larry Steinman, M.D.
Prof. Steinman is the George A. Zimmermann Professor of Neurology and Neurological Sciences, Pediatrics and Genetics and Chair of the Interdepartmental Program in Immunology at Stanford University. He received the Senator Jacob Javits Neuroscience Investigator Award from the U.S. Congress in 1998. Prof. Steinman was awarded the Friedrich Sasse Prize for Outstanding Contributions in Immunology from the Free University of Berlin in 1994 and the John M. Dystel Prize for Outstanding Contributions in Multiple Sclerosis Research from the American Academy of Neurology and the National MS Society in 2004. Prof. Steinman is the co-discoverer of Tysabri® which is used in the treatment of multiple sclerosis. He is also a Co-Founder of Neurocrine Biosciences, Inc., Bayhill Therapeutics, Inc. and Nuon Therapeutics, Inc.
Prof. Sir Marc Feldmann, F.Med.Sci., F.A.A., F.R.S.
Prof. Feldmann is a Professor and the Director of the Kennedy Institute of Rheumatology at Imperial College, London. Prof. Feldmann, together with his collaborator, Prof. Ravinder Maini, was awarded the Crafoord Prize in 2000 and the Albert Lasker Award for Clinical Medical Research in 2003 for their discovery that anti-TNF therapy was an effective treatment for rheumatoid arthritis. Prof. Feldmann was European Inventor of the Year in the lifetime achievement category and was awarded the John Curtin Medal of the Australian National University in 2007. He is a Co-Founder of Nuon Therapeutics, Inc.
|
|
|
|
|
|
